Imprinted Diagnostics secures £144k for portable heart-attack diagnostic platform

A portable heart-attack testing platform is being developed by Imprinted Diagnostics Limited following an approximately £144k funding round. Based in Manchester, the company focuses on multi-test devices that utilize cold-chain-free reagents.

The startup was incorporated in November 2025 and aims to provide fast and accurate clinical assessments for pre-hospital triage. These tools are intended to save lives by addressing critical healthcare gaps in underserved regions.

According to LinkedIn data, the business currently employs three people in the hospitals and health care industry and maintains the website imprinteddiagnostics.com. This latest capital injection results in an estimated post-money valuation of £864k for the medical and dental instrument and supplies manufacturer. The round was finalized with share allotments and filings completed in July 2026.